相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
Nianhang Chen et al.
CLINICAL PHARMACOKINETICS (2017)
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
J. Kroenke et al.
LEUKEMIA (2017)
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial
Francesca R. Mauro et al.
LEUKEMIA & LYMPHOMA (2017)
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
A. Chanan-Khan et al.
LEUKEMIA (2017)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Philip A. Thompson et al.
BLOOD (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
Pavel Otahal et al.
ONCOIMMUNOLOGY (2016)
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor
Michael Y. Choi et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
Alexandra Albertsson-Lindblad et al.
BLOOD (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Bendamustine plus rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: AWisconsin Oncology Network Study
Julie E. Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Candida Vitale et al.
CLINICAL CANCER RESEARCH (2016)
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
Christian Maurer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Barbara Eichhorst et al.
LANCET ONCOLOGY (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
Clemens M. Wendtner et al.
LEUKEMIA & LYMPHOMA (2016)
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
Julio C. Chavez et al.
LEUKEMIA RESEARCH (2016)
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity
Ruth Eichner et al.
NATURE MEDICINE (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A review of the venous thrombotic issues associated with multiple myeloma
Despina Fotiou et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
A. Buehler et al.
BLOOD CANCER JOURNAL (2016)
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
Rebekah L. Browning et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia
Anthony R. Mato et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Targeted therapies in CLL: mechanisms of resistance and strategies for management
Jennifer A. Woyach et al.
BLOOD (2015)
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Chan Yoon Cheah et al.
BLOOD (2015)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Practical Management of Lenalidomide-Related Rash
Sara M. Tinsley et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Petra Langerbeins et al.
FUTURE ONCOLOGY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
V. Goede et al.
LEUKEMIA (2015)
Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells
Giovanni D'Arena et al.
LEUKEMIA & LYMPHOMA (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels
Tait D. Shanafelt et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
Stefania Fiorcari et al.
HAEMATOLOGICA (2015)
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Luciano J. Costa et al.
LEUKEMIA & LYMPHOMA (2015)
Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma
Chaitra Ujjani et al.
LEUKEMIA & LYMPHOMA (2015)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
Aristoteles Giagounidis et al.
ANNALS OF HEMATOLOGY (2014)
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
Constantine S. Tam et al.
BLOOD (2014)
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
Li Jia et al.
BLOOD (2014)
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
Jessie-F. Fecteau et al.
BLOOD (2014)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Long-term follow-up of a phase 2 trial of single agent lenalidomidein previously untreated patients with chronic lymphocytic leukaemia
Christine I. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia
Rossana Maffei et al.
EXPERIMENTAL HEMATOLOGY (2014)
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia
Franz J. Gassner et al.
HAEMATOLOGICA (2014)
Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
Danelle F. James et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
A. Thakurta et al.
LEUKEMIA (2014)
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
Kami Maddocks et al.
LEUKEMIA RESEARCH (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
Leticia Huergo-Zapico et al.
PLOS ONE (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
Andrea Acebes-Huerta et al.
BIOMED RESEARCH INTERNATIONAL (2014)
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
Annemiek Broyl et al.
BLOOD (2013)
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment
Angela Schulz et al.
BLOOD (2013)
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Paolo Strati et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
Tait D. Shanafelt et al.
BLOOD (2013)
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
Alan G. Ramsay et al.
BLOOD (2013)
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
Ling-Hua Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia Potential Clinical Implications
John C. Riches et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Xavier C. Badoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Novel, Non-canonical Splice Variant of the Ikaros Gene Is Aberrantly Expressed in B-cell Lymphoproliferative Disorders
Daria Capece et al.
PLOS ONE (2013)
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
Iwona Hus et al.
PLOS ONE (2013)
RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans
Anja Troeger et al.
BLOOD (2012)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner
Aisha Masood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
N. Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells
Rossana Maffei et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L
Montserrat Cols et al.
JOURNAL OF IMMUNOLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Clemens-Martin Wendtner et al.
LEUKEMIA & LYMPHOMA (2012)
Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia
Georg Aue et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications
Katy Billot et al.
BLOOD (2011)
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
Sarah E. M. Herman et al.
BLOOD (2011)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Xavier C. Badoux et al.
BLOOD (2011)
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
Xavier C. Badoux et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Nurse-like cells show deregulated expression of genes involved in immunocompetence
Nupur Bhattacharya et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Regulatory T Cells Predict the Time to Initial Treatment in Early Stage Chronic Lymphocytic Leukemia
Lukas Weiss et al.
CANCER (2011)
Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response
Asher Chanan-Khan et al.
CANCER (2011)
Treatment With Lenalidomide Modulates T-Cell Immunophenotype and Cytokine Production in Patients With Chronic Lymphocytic Leukemia
Bang-Ning Lee et al.
CANCER (2011)
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
Giovanni D'Arena et al.
LEUKEMIA RESEARCH (2011)
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
Rossana Maffei et al.
BLOOD (2010)
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells
Irina Idler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses
Nianhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2010)
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Taimur Sher et al.
LEUKEMIA & LYMPHOMA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression
Wei Ding et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
Gondi Kumar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia
K. Giannopoulos et al.
LEUKEMIA (2009)
Enhanced formation and survival of CD4+CD25hi Foxp3+T-cells in chronic lymphocytic leukemia
Margot Jak et al.
LEUKEMIA & LYMPHOMA (2009)
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
Ilaria Iacobucci et al.
BLOOD (2008)
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella et al.
BLOOD (2008)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Charles G. Mullighan et al.
NATURE (2008)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia
Stefano Molica et al.
LEUKEMIA RESEARCH (2007)
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia
Luca Laurenti et al.
LEUKEMIA RESEARCH (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
A Chanan-Khan et al.
BLOOD (2005)
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
FJ Hernandez-Ilizaliturri et al.
CLINICAL CANCER RESEARCH (2005)
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia
S Scrivener et al.
LEUKEMIA & LYMPHOMA (2003)
Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia
N Tsukada et al.
BLOOD (2002)
分享论文
